ST. LOUIS, June 2 /PRNewswire-FirstCall/ -- (BULLETIN BOARD: SOLUQ) -- Solutia Pharmaceutical Services Division (PSD) -- the drug development services provider -- has extended its capability in the supply of highly potent drugs, such as oncologics, to the development and scale-up of anti- cancer drug conjugates.
"The concept of conjugated therapeutics represents the next frontier of anti-cancer treatment," says Jason Bertola, Solutia PSD's global business development manager for highly potent API supply. "The application of this technology can decrease a highly potent drug compound's toxicity to healthy cells while increasing its selectivity to better target tumor cells. As a result, once approved by the FDA, new oncologic treatments may be safer for patients in higher doses, and with reduced risk of side effects. In the case of one conjugate, the maximum tolerated dose for the treatment increased by fivefold. The potential for this technology to dramatically impact the quality of life for cancer patients is incredibly promising."
Solutia PSD is currently supporting the development of drug conjugates on behalf of clients that are leaders in this emerging field. The projects involve process research and development as well as scale-up and production of batches of conjugated APIs for clinical trials.
"Thanks to the 2003 launch of our state-of-the-art containment facility, Solutia PSD is privileged to offer the right combination of know-how, infrastructure and equipment to support the scale-up of these remarkable molecules," says Mark Griffiths, director of operations for Solutia PSD. "The hybrid nature of these compounds makes their processing, purification and analysis highly technical. Work with them demands a multidisciplinary approach combining expertise in the fields of both small and large molecules for process R&D, scale-up and current good manufacturing practice (cGMP) and must also be supported by high-potency and highly specialized analytical capabilities."
The term 'drug conjugates' describes the concept of covalently binding highly active drugs (in most cases a bioactive tumor agent) to a water-soluble polymeric carrier or a protein, such as an antibody. This process enhances the cell specificity of the bioactive drug, so it can more selectively attack the target tumor, a feature that decreases its toxicity to healthy cells, and offers enhanced permeability and retention in tumor cells.
Solutia PSD believes this niche market represents an important area of future industry growth. "More than 10 new polymer-drug conjugates have entered Phase I or Phase II clinical trials in the last decade," says Bertola. "With the promising Phase II results of some representatives of this class, the first expected FDA approval of the new therapeutic cancer treatment should generate significant interest and investment. Needless to say, Solutia PSD is enthusiastic about the potential for this technology to improve the lives of cancer patients."
Solutia ( http://www.solutia.com/ ) uses world-class skills in applied chemistry to create value-added solutions for customers, whose products improve the lives of consumers every day. Solutia's Pharmaceutical Services Division (Solutia PSD) combines the world-class chemistry skills of CarboGen and AMCIS, the clinical expertise of Axio Research, and the expert resources of Solutia Pharmaceutical Advisors, to provide seamless development and commercialization services for leading pharmaceutical and biotechnology companies. In addition, Solutia is a world leader in performance films for laminated safety glass and after-market applications; specialties such as water treatment chemicals, heat transfer fluids and aviation hydraulic fluid; and an integrated family of nylon products including high-performance polymers and fibers.
Solutia ....Solutions for a Better Life.
Solutia Pharmaceutical Services Division